Polyp of maxillary sinus

Summary

Polyp of maxillary sinus (MONDO:0021412) is a disease. A subtype of paranasal sinus disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	polyp of maxillary sinus
Mondo ID	MONDO:0021412
NCIT	C3931
SNOMED CT	29074008
UMLS	C0264239
MedGen	120498
Anatomy (UBERON)	UBERON:0001764
Is cancer (heuristic)	no

Also known as: maxillary antral polyp · maxillary sinus polyp · polyp of the maxillary sinus

Disease family

This is a subtype of paranasal sinus disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › otorhinolaryngologic disease › nasal disorder › paranasal sinus disorder › polyp of maxillary sinus

Related subtypes (6): paranasal sinus neoplasm, sinusitis, maxillary sinus cholesteatoma, polyp of sphenoidal sinus, polyp of frontal sinus, polyp of ethmoidal sinus

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.